Sweden Health Podcasts Sweden Health RSS feedThis is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Newly approved drugs for AML in the US
New drugs for acute myeloid leukemia (AML) are constantly being developed. In this video, recorded at the 23rd Congress of the European Hematological Association (EHA) 2018, held in Stockholm, Sweden,... Author: VJHemOnc Added: 07/31/2018 (Source: Oncology Tube)
Source: Oncology Tube - July 31, 2018 Category: Cancer & Oncology Source Type: podcasts

Developments in targeted AML therapies: venetoclax, quizartinib & amp; gilteritinib
Speaking from the 23rd Congress of the European Hematological Association (EHA) 2018 in Stockholm, Sweden, Naval Daver, MD, of the MD Anderson Cancer Center, Houston, TX, speaks about three new target... Author: VJHemOnc Added: 07/31/2018 (Source: Oncology Tube)
Source: Oncology Tube - July 31, 2018 Category: Cancer & Oncology Source Type: podcasts

Improved survival in MM with thalidomide before and after ASCT
The 23rd congress of the European Haematology Association (EHA) 2018, held in Stockholm, Sweden, presented exciting data from multiple myeloma (MM) trials. In this interview, Niels van de Donk, MD, Ph... Author: VJHemOnc Added: 07/24/2018 (Source: Oncology Tube)
Source: Oncology Tube - July 24, 2018 Category: Cancer & Oncology Source Type: podcasts

Multiple Myeloma trial highlights: ARROW, OPTIMISMM & amp; ALCYONE
The 23rd Congress of the European Hematological Association (EHA) 2018 in Stockholm, Sweden, saw many researchers presenting the newest data from their recent clinical trials. In this video, Mohamad M... Author: VJHemOnc Added: 07/23/2018 (Source: Oncology Tube)
Source: Oncology Tube - July 23, 2018 Category: Cancer & Oncology Source Type: podcasts

Using MRD to inform allocation of stem cell transplants in ALL and AML
Fabio Guolo, MD, of the University of Genoa, Genoa, Italy, spoke to us at the 23rd Congress of the European Hematology Association (EHA) 2018, held in Stockholm, Sweden, about how measurable residual ... Author: VJHemOnc Added: 07/18/2018 (Source: Oncology Tube)
Source: Oncology Tube - July 18, 2018 Category: Cancer & Oncology Source Type: podcasts

Advances in targeted therapies for ALL
Speaking from the 23rd Congress of the European Hematology Association (EHA) 2018, held in Stockholm, Sweden, David Marks, MBBS, PhD, FRACP, FRCPath, of University Hospitals Bristol NHS Foundation Tru... Author: VJHemOnc Added: 07/18/2018 (Source: Oncology Tube)
Source: Oncology Tube - July 18, 2018 Category: Cancer & Oncology Source Type: podcasts

The last year in CLL
Speaking from the 23rd Congress of the European Hematology Association (EHA) 2018, held in Stockholm, Sweden, John Seymour, MBBS, FRACP, PhD, of the Peter MacCallum Cancer Center, Victoria, Australia,... Author: VJHemOnc Added: 07/18/2018 (Source: Oncology Tube)
Source: Oncology Tube - July 18, 2018 Category: Cancer & Oncology Source Type: podcasts

An update from the Nordic Myeloma Study Group
The 23rd Congress of the European Hematology Association (EHA) 2018, held in Stockholm, Sweden, saw many researchers reporting their most recent clinical trial data. Here, Hareth Nahi, MD, of the Karo... Author: VJHemOnc Added: 07/18/2018 (Source: Oncology Tube)
Source: Oncology Tube - July 18, 2018 Category: Cancer & Oncology Source Type: podcasts

MRD: common misconceptions and clinical considerations
Speaking from the 23rd Congress of the European Hematology Association (EHA) 2018, held in Stockholm, Sweden, Fabio Guolo, MD, of the University of Genoa, Genoa, Italy, discusses misconceptions around... Author: VJHemOnc Added: 07/18/2018 (Source: Oncology Tube)
Source: Oncology Tube - July 18, 2018 Category: Cancer & Oncology Source Type: podcasts

Drug cost vs. toxicity in MM
Hareth Nahi, MD, of the Karolinska Institutet, Stockholm, Sweden, discusses the association between drug cost and toxicity at the 23rd Congress of the European Hematology Association (EHA) 2018, held ... Author: VJHemOnc Added: 07/18/2018 (Source: Oncology Tube)
Source: Oncology Tube - July 18, 2018 Category: Cancer & Oncology Source Type: podcasts

Novel anti-BCMA immunotherapies have unprecedented responses
In this interview at the 23rd Congress of European Haematology Association (EHA) 2018, held in Stockholm, Sweden, Gareth Morgan, MD, PhD, FRCP, FRCPath, from the University of Arkansas for Medical Sci... Author: VJHemOnc Added: 07/18/2018 (Source: Oncology Tube)
Source: Oncology Tube - July 18, 2018 Category: Cancer & Oncology Source Type: podcasts

Platinum-Based Chemo Doublets_ Backbone for NSCLC Treatment [720p]
Dr. Jack West, Swedish Cancer Institute, identifies the platinum-based chemotherapy doublet as the backbone of first-line treatment for the majority of NSCLC patients. Author: cancergrace Added: 05/16/2018 (Source: Oncology Tube)
Source: Oncology Tube - May 16, 2018 Category: Cancer & Oncology Source Type: podcasts

What is the Role of Bevacizumab in Stage IV NSCLC_ [720p]
Dr. Jack West, Swedish Cancer Institute, discusses the anti-angiogenic agent bevacizumab (Avastin) and the trial evidence of its efficacy for non-squamous NSCLC. Author: cancergrace Added: 05/15/2018 (Source: Oncology Tube)
Source: Oncology Tube - May 16, 2018 Category: Cancer & Oncology Source Type: podcasts

Histology-Specific Regimens - Squamous [720p]
Dr. Jack West, Swedish Cancer Institute, reviews the choices for a first-line chemotherapy regimen based on a squamous histology Author: cancergrace Added: 05/15/2018 (Source: Oncology Tube)
Source: Oncology Tube - May 15, 2018 Category: Cancer & Oncology Source Type: podcasts

Histology-Specific Recommendations - Large-Cell Neuroendocrine [720p]
Dr. Jack West, Swedish Cancer Institute, identifies the best choice for first-line chemotherapy for large-cell neuroendocrine histology. Author: cancergrace Added: 05/15/2018 (Source: Oncology Tube)
Source: Oncology Tube - May 15, 2018 Category: Cancer & Oncology Source Type: podcasts